Serial Analysis and Comparison of Mutation Profiles in Decitabine-treated Myeloid Sarcoma and Subsequent Acute Myeloid Leukemia Using Next-Generation Sequencing

참고문헌 (10)

1. Avni B, "Myeloid sarcoma : current approach and therapeutic options", Ther Adv Hematol, 2, pp.309~316 (2011)
2. Li Z, "Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma", Leukemia, 29, pp.2113~2116 (2015)
3. Greenland NY, "Genomic analysis in myeloid sarcoma and comparison with paired acute myeloid leukemia", Hum Pathol, 108, pp.76~83 (2021)
4. Kashofer K, "Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing", Leuk Lymphoma, 59, pp.501~504 (2018)
5. Werstein B, "Molecular discordance between myeloid sarcomas and concurrent bone marrows occurs in actionable genes and is associated with worse overall survival", J Mol Diagn, 22, pp.338~345 (2020)
6. Choi M, "RTK-RAS pathway mutation is enriched in myeloid sarcoma", Blood Cancer J, 8, pp.43~ (2018)
7. Gornicec M, "Evidence for a role of decitabine in the treatment of myeloid sarcoma", Ann Hematol, 96, pp.505~506 (2017)
8. Evers D, "Activity of decitabine in pericardial myeloid sarcoma", Int J Hematol, 108, pp.121~122 (2018)
9. Itzykson R, "Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias", Leukemia, 25, pp.1147~1152 (2011)
10. Bejar R, "TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients", Blood, 124, pp.2705~2712 (2014)

관련 논문AI추천